218 related articles for article (PubMed ID: 16116344)
1. Two inotropes with different mechanisms of action: contractile, PDE-inhibitory and direct myofibrillar effects of levosimendan and enoximone.
Szilágyi S; Pollesello P; Levijoki J; Haikala H; Bak I; Tósaki A; Borbély A; Edes I; Papp Z
J Cardiovasc Pharmacol; 2005 Sep; 46(3):369-76. PubMed ID: 16116344
[TBL] [Abstract][Full Text] [Related]
2. The effects of levosimendan and OR-1896 on isolated hearts, myocyte-sized preparations and phosphodiesterase enzymes of the guinea pig.
Szilágyi S; Pollesello P; Levijoki J; Kaheinen P; Haikala H; Edes I; Papp Z
Eur J Pharmacol; 2004 Feb; 486(1):67-74. PubMed ID: 14751410
[TBL] [Abstract][Full Text] [Related]
3. Positive inotropic effect of levosimendan is correlated to its stereoselective Ca2+-sensitizing effect but not to stereoselective phosphodiesterase inhibition.
Kaheinen P; Pollesello P; Hertelendi Z; Borbély A; Szilágyi S; Nissinen E; Haikala H; Papp Z
Basic Clin Pharmacol Toxicol; 2006 Jan; 98(1):74-8. PubMed ID: 16433895
[TBL] [Abstract][Full Text] [Related]
4. The two mechanisms of action of racemic cardiotonic EMD 53998, calcium sensitization and phosphodiesterase inhibition, reside in different enantiomers.
Lues I; Beier N; Jonas R; Klockow M; Haeusler G
J Cardiovasc Pharmacol; 1993 Jun; 21(6):883-92. PubMed ID: 7687712
[TBL] [Abstract][Full Text] [Related]
5. Troponin C-mediated calcium sensitization by levosimendan accelerates the proportional development of isometric tension.
Haikala H; Levijoki J; Lindén IB
J Mol Cell Cardiol; 1995 Oct; 27(10):2155-65. PubMed ID: 8576932
[TBL] [Abstract][Full Text] [Related]
6. ORM-3819 promotes cardiac contractility through Ca(2+) sensitization in combination with selective PDE III inhibition, a novel approach to inotropy.
Nagy L; Pollesello P; Haikala H; Végh Á; Sorsa T; Levijoki J; Szilágyi S; Édes I; Tóth A; Papp Z; Papp JG
Eur J Pharmacol; 2016 Mar; 775():120-9. PubMed ID: 26872993
[TBL] [Abstract][Full Text] [Related]
7. Pharmacological effects of ATI22-107 [2-(2-{2-[2-chloro-4-(6-oxo-1,4,5,6-tetrahydro-pyridazin-3-yl)-phenoxy]-acetylamino}-ethoxymethyl)-4-(2-chloro-phenyl)-6-methyl-1,4-dihydro-pyridine-3,5-dicarboxylic acid dimethyl ester)], a novel dual pharmacophore, on myocyte calcium cycling and contractility.
Jung AS; Quaile MP; Mills GD; Bednarik DP; Houser SR; Margulies KB
J Pharmacol Exp Ther; 2005 Feb; 312(2):517-24. PubMed ID: 15550574
[TBL] [Abstract][Full Text] [Related]
8. Relation of positive inotropic and chronotropic effects of pimobendan, UD-CG 212 Cl, milrinone and other phosphodiesterase inhibitors to phosphodiesterase III inhibition in guinea-pig heart.
Brunkhorst D; v der Leyen H; Meyer W; Nigbur R; Schmidt-Schumacher C; Scholz H
Naunyn Schmiedebergs Arch Pharmacol; 1989 May; 339(5):575-83. PubMed ID: 2549430
[TBL] [Abstract][Full Text] [Related]
9. The role of cAMP- and cGMP-dependent protein kinases in the cardiac actions of the new calcium sensitizer, levosimendan.
Haikala H; Kaheinen P; Levijoki J; Lindén IB
Cardiovasc Res; 1997 Jun; 34(3):536-46. PubMed ID: 9231037
[TBL] [Abstract][Full Text] [Related]
10. Comparison of enoximone, amrinone, or levosimendan enriched St. Thomas' hospital cardioplegic solutions used for myocardial preservation in isolated guinea pig hearts.
Köksal C; Süzer O; Bozkurt AK; Köseoğlu S
Acta Medica (Hradec Kralove); 2002; 45(3):93-7. PubMed ID: 12515045
[TBL] [Abstract][Full Text] [Related]
11. Effects of Levosimendan, a cardiotonic agent targeted to troponin C, on cardiac function and on phosphorylation and Ca2+ sensitivity of cardiac myofibrils and sarcoplasmic reticulum in guinea pig heart.
Edes I; Kiss E; Kitada Y; Powers FM; Papp JG; Kranias EG; Solaro RJ
Circ Res; 1995 Jul; 77(1):107-13. PubMed ID: 7788868
[TBL] [Abstract][Full Text] [Related]
12. Effects of several newer cardiotonic drugs on cardiac cyclic AMP metabolism.
Ahn HS; Eardley D; Watkins R; Prioli N
Biochem Pharmacol; 1986 Apr; 35(7):1113-21. PubMed ID: 2421728
[TBL] [Abstract][Full Text] [Related]
13. Contribution of cAMP-phosphodiesterase inhibition and sensitization of the contractile proteins for calcium to the inotropic effect of pimobendan in the failing human myocardium.
Böhm M; Morano I; Pieske B; Rüegg JC; Wankerl M; Zimmermann R; Erdmann E
Circ Res; 1991 Mar; 68(3):689-701. PubMed ID: 1660359
[TBL] [Abstract][Full Text] [Related]
14. The novel cardiotonic agent EMD 53 998 is a potent "calcium sensitizer".
Beier N; Harting J; Jonas R; Klockow M; Lues I; Haeusler G
J Cardiovasc Pharmacol; 1991 Jul; 18(1):17-27. PubMed ID: 1719287
[TBL] [Abstract][Full Text] [Related]
15. High selectivity for inhibition of phosphodiesterase III and positive inotropic effects of MCI-154 in guinea pig myocardium.
Bethke T; Meyer W; Schmitz W; Scholz H; Wenzlaff H; Armah BI; Brückner R; Raap A
J Cardiovasc Pharmacol; 1993 Jun; 21(6):847-55. PubMed ID: 7687707
[TBL] [Abstract][Full Text] [Related]
16. Effects of levosimendan on myocardial contractility and Ca2+ transients in aequorin-loaded right-ventricular papillary muscles and indo-1-loaded single ventricular cardiomyocytes of the rabbit.
Sato S; Talukder MA; Sugawara H; Sawada H; Endoh M
J Mol Cell Cardiol; 1998 Jun; 30(6):1115-28. PubMed ID: 9689586
[TBL] [Abstract][Full Text] [Related]
17. Cardiac effects of R 79595 and its isomers (R 80122 and R 80123) in an acute heart failure model. A new class of cardiotonic agents with highly selective phosphodiesterase III inhibitory properties.
Schneider J; Beck E; Heers C; Conrad C; de Chaffoy de Courcelles D; Wilffert B; Peters T
Naunyn Schmiedebergs Arch Pharmacol; 1992 Nov; 346(5):563-72. PubMed ID: 1470228
[TBL] [Abstract][Full Text] [Related]
18. Role of phosphodiesterases III and IV in the modulation of vascular cyclic AMP content by the NO/cyclic GMP pathway.
Eckly AE; Lugnier C
Br J Pharmacol; 1994 Oct; 113(2):445-50. PubMed ID: 7834194
[TBL] [Abstract][Full Text] [Related]
19. Levosimendan, a new inotropic and vasodilator agent.
Toller WG; Stranz C
Anesthesiology; 2006 Mar; 104(3):556-69. PubMed ID: 16508404
[TBL] [Abstract][Full Text] [Related]
20. Calcium sensitization as new principle of inotropic therapy in end-stage heart failure?
Zimmermann N; Boknik P; Gams E; Herzig JW; Neumann J; Scholz H
Eur J Cardiothorac Surg; 1998 Jul; 14(1):70-5. PubMed ID: 9726618
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
